{"title":"[The progress of novel drug delivery systems].","authors":"Hui-le Gao, Xin-guo Jiang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The development of pharmaceuticals has been providing many kinds of novel drug delivery\nsystems, which are important for improving therapeutic effect and one of the most important fields in pharmaceutics.\nAccording to their application, we can generally divide the novel drug delivery systems into three categories:\nquickly performed drug delivery system, long-term drug delivery system and high effective drug delivery system.\nSome diseases, such as asthma, angina pectoris and migraine, require therapeutics urgently, and the drugs have to\nbe absorbed in several minutes. Therefore, quickly performed drug delivery systems are developed, such as oral\ndisintegrating tablets and nasal spray. For normal tablets and capsules, especially the drugs with short blood\nhalf life, the drug concentration in blood shows obvious peak-valley phenomenon, which reduces the therapeutic\neffect and requires multiple administration. To solve this problem, sustained drug release system was developed,\nwhich could release the drugs slowly and sustainably even in zero-order kinetics. The pulse drug delivery system\nwas developed that can delayed and pulsed release drug for one or several times. This system is especially\nuseful in the management of asthma and heart disease, which are often found in midnight or early morning when\npatients are in bed. Transdermal drug delivery system could release drugs sustainably and deliver the drugs\nthrough skin to blood circulation, providing long term activity. The water-insoluble drugs are difficult for\npharmaceutical development, thus many methods were developed to improve the solubility and bioavailability of\ndrugs. Although biopharmaceuticals are important for disease treatment, the application shadows by the poor\nstability and low bioavailability. Thus the biopharmaceutical delivery system was developed, which mainly\nfocused on structure modification and encapsulation by carriers. Considering therapeutic effect requires\ninteraction between drugs and their targets, it is important to deliver drugs to their targets. Therefore, targeting\ndelivery systems were developed, which mainly based on the nanoparticles. Furthermore, on-demand release\ndrug delivery systems are also developed with the property of environment-triggered drug release. In conclusion,\nthe novel drug delivery systems were reviewed in this study.</p>","PeriodicalId":35924,"journal":{"name":"药学学报","volume":"52 2","pages":"181-8"},"PeriodicalIF":0.0000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"药学学报","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The development of pharmaceuticals has been providing many kinds of novel drug delivery
systems, which are important for improving therapeutic effect and one of the most important fields in pharmaceutics.
According to their application, we can generally divide the novel drug delivery systems into three categories:
quickly performed drug delivery system, long-term drug delivery system and high effective drug delivery system.
Some diseases, such as asthma, angina pectoris and migraine, require therapeutics urgently, and the drugs have to
be absorbed in several minutes. Therefore, quickly performed drug delivery systems are developed, such as oral
disintegrating tablets and nasal spray. For normal tablets and capsules, especially the drugs with short blood
half life, the drug concentration in blood shows obvious peak-valley phenomenon, which reduces the therapeutic
effect and requires multiple administration. To solve this problem, sustained drug release system was developed,
which could release the drugs slowly and sustainably even in zero-order kinetics. The pulse drug delivery system
was developed that can delayed and pulsed release drug for one or several times. This system is especially
useful in the management of asthma and heart disease, which are often found in midnight or early morning when
patients are in bed. Transdermal drug delivery system could release drugs sustainably and deliver the drugs
through skin to blood circulation, providing long term activity. The water-insoluble drugs are difficult for
pharmaceutical development, thus many methods were developed to improve the solubility and bioavailability of
drugs. Although biopharmaceuticals are important for disease treatment, the application shadows by the poor
stability and low bioavailability. Thus the biopharmaceutical delivery system was developed, which mainly
focused on structure modification and encapsulation by carriers. Considering therapeutic effect requires
interaction between drugs and their targets, it is important to deliver drugs to their targets. Therefore, targeting
delivery systems were developed, which mainly based on the nanoparticles. Furthermore, on-demand release
drug delivery systems are also developed with the property of environment-triggered drug release. In conclusion,
the novel drug delivery systems were reviewed in this study.
药学学报Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.20
自引率
0.00%
发文量
0
期刊介绍:
Acta Pharmaceutica Sinica B (APSB) is a bimonthly English peer-reviewed online journal in ScienceDirect, which publishes significant original research articles, communications and high quality reviews of recent advances. APSB encourages submissions from all areas of pharmaceutical sciences, including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
APSB is a part of the series Acta Pharmaceutica Sinica, which was founded in 1953. The journal is co-published by Elsevier B.V., in association with the Institute of MateriaMedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.